Enlivex Therapeutics (NASDAQ:ENLV) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Enlivex Therapeutics (NASDAQ:ENLV) from a hold rating to a sell rating in a research report sent to investors on Saturday.

Other research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Friday, June 26th. Zacks Research upgraded Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Enlivex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $247.50.

Enlivex Therapeutics Price Performance

NASDAQ:ENLV opened at $1.58 on Friday. The firm has a market capitalization of $26.59 million, a price-to-earnings ratio of -0.19 and a beta of 1.60. The company’s 50-day moving average is $6.08 and its two-hundred day moving average is $11.51. Enlivex Therapeutics has a 1-year low of $1.53 and a 1-year high of $31.50.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in Enlivex Therapeutics by 99.4% during the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after buying an additional 156,336 shares during the period. HRT Financial LP raised its stake in shares of Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after acquiring an additional 135,198 shares during the period. Bank of America Corp DE raised its stake in shares of Enlivex Therapeutics by 53.2% in the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after acquiring an additional 45,303 shares during the period. Jane Street Group LLC raised its stake in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after acquiring an additional 19,132 shares during the last quarter. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.